Press Releases

Frontier Biotechnologies Inc. (Frontier) is pleased to announce our partnership with Avacare Health Group (Avacare Health) to expand access for Albuvirtide to people living with HIV (PLHIV) in Kenya, Nigeria, Tanzania and Malawi, thus reaching the key countries in eastern and western Africa.There ar...
  • 2022-07-25  15:45:07
In October 2021, in the “13th National AIDS and Hepatitis C Conference of the Chinese Medical Association”, organized by the AIDS Group of the Chinese Society of Infectious Diseases, Chinese Medical Association, the Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS (2021 Edition) (hereinaft...
  • 2022-07-05  15:42:55
On July 18, 2021 local time, the 11th International AIDS Society (IAS) Conference on HIV Science was held in Berlin, Germany. At this conference, Frontier Biotech (stock code: 688221.SH) released the key research results of its Phase III clinical study (TALENT study) on the long-acting anti-HIV-1 fu...
  • 2022-07-05  15:39:10
On June 10, 2022, the Journal Of Infection (ISSN: 0163-4453, eISSN: 1532-2742), an authoritative international medical journal, published online the 48-week final results of Phase III clinical TALENT study on Frontier Biotech’s long-acting anti-HIV fusion inhibitor Albuvirtide (ABT). In 2018, based ...
  • 2022-06-22  15:36:07
Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual th...
  • 2022-06-22  10:08:57
Shanghai Ruijin Hospital recently announced that it has initiated an investigator-initiated clinical trial (IIT) to evaluate the safety and efficacy of Bofutrelvir administered by inhalation for post-exposure prophylaxis in close contacts of COVID-19 (NCT05415241). It is a single-arm, open-label, m...
  • 2022-06-15  10:08:28
Frontier Biotech (stock code: 688221.SH) announced that the Phase II/III clinical study protocol of FB2001 (generic name: Bofutrelvir) is approved by the Center for Drug Evaluation, NMPA. The study is a worldwide multi-center, randomized, double-blind and placebo-controlled Phase II/III trial to ev...
  • 2022-04-27  10:07:38
On July 15, 2021, The openning ceremony of a new state of the art peptide manufacture facility was held in Jintang, Chengdu. The successful completion of the facility marks the successful industrialization of Aikening® in Jintang.Aiming at intelligent manufacturing, high efficiency and eco syst...
  • 2021-08-31  16:54:43
Nanjing, China, October 28, 2020 -- Frontier Biotechnologies Inc.( Frontier Biotech), a commercial-stage biopharmaceutical company focused on discovering, development, manufacturing, and commercialization of innovative medicines, today announced its completion of the Initial Public Offering (IPO) an...
  • 2020-10-28  09:04:39
July 21, 2021 Nanjing, China. Frontier Biotech (stock code: 688221.SH) announces that it signs an agreement with R-Pharm, JSC, one of the largest pharmaceutical companies in Russia, for registration and commercialization of Aikening® (generic name: Albuvirtide) in Russia. Cheryl Tan, Global H...
  • 2021-08-30  15:52:59
Frontier Biotech (688221.SH) recently received the Certificate of Registration of Foreign Medicines issued by the Ministry of Health of Ecuador for companys innovative anti-HIV drug AikeningTM (Albuvirtide for injection 160 mg) to be marketed in Ecuador.AlfusidTM is the registered trade mark of Aike...
  • 2021-03-18  19:58:20

Develop Innovative Therapies to Better Human Lives